Biotechnology research firm Creative Biolabs is advancing the field of next-generation probiotics (NGPs) through sophisticated microbial engineering and targeted strain development. The company's approach moves beyond traditional probiotics by focusing on specific microbial manipulations that could potentially address complex health challenges.
Researchers are particularly interested in specific bacterial strains like Akkermansia muciniphila, which demonstrates unique capabilities in enhancing intestinal barrier function, modulating inflammation, and improving metabolic health. By leveraging advanced genetic engineering technologies such as CRISPR/Cas9, Creative Biolabs can design engineered strains with precise capabilities.
The company's comprehensive research services include advanced analytical techniques like 16S rRNA sequencing, metagenomics, and metatranscriptomics. These methods enable detailed characterization of microbial strains and their potential therapeutic applications.
A key differentiator in Creative Biolabs' approach is its rigorous in vivo safety studies. By utilizing animal models including experimental endocarditis rat models and immunodeficient mouse models, researchers can evaluate the functionality and safety of engineered microbial strains before potential clinical applications.
The shift towards next-generation probiotics represents a significant advancement in microbiome science, offering more personalized and targeted approaches to understanding and potentially treating various health conditions. By providing detailed strain optimization and characterization services, Creative Biolabs is contributing to the translation of microbiome research from basic scientific understanding to practical therapeutic interventions.
